These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 24817473)

  • 1. One-stage and two-stage designs for phase II clinical trials with survival endpoints.
    Whitehead J
    Stat Med; 2014 Sep; 33(22):3830-43. PubMed ID: 24817473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing phase II studies in cancer with time-to-event endpoints.
    Owzar K; Jung SH
    Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
    Lai X; Zee BC
    Trials; 2015 Jun; 16():250. PubMed ID: 26037094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-stage phase II oncology designs using short-term endpoints for early stopping.
    Kunz CU; Wason JM; Kieser M
    Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian methods for setting sample sizes and choosing allocation ratios in phase II clinical trials with time-to-event endpoints.
    Cotterill A; Whitehead J
    Stat Med; 2015 May; 34(11):1889-903. PubMed ID: 25620687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exact two-stage designs for phase II activity trials with rank-based endpoints.
    Wilding GE; Shan G; Hutson AD
    Contemp Clin Trials; 2012 Mar; 33(2):332-41. PubMed ID: 22074983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The power of phase II end-points for different possible mechanisms of action of an experimental treatment.
    Wason JM; Dentamaro A; Eisen TG
    Eur J Cancer; 2015 May; 51(8):984-92. PubMed ID: 25840669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interval and point estimation in adaptive Phase II trials with binary endpoint.
    Nhacolo A; Brannath W
    Stat Methods Med Res; 2019 Sep; 28(9):2635-2648. PubMed ID: 29921157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving phase II oncology trials using best observed RECIST response as an endpoint by modelling continuous tumour measurements.
    Lin CJ; Wason JMS
    Stat Med; 2017 Dec; 36(29):4616-4626. PubMed ID: 28850689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal decision-making in oncology development programs based on probability of success for phase III utilizing phase II/III data on response and overall survival.
    Götte H; Xiong J; Kirchner M; Demirtas H; Kieser M
    Pharm Stat; 2020 Nov; 19(6):861-881. PubMed ID: 32662598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-stage phase II survival trial design.
    Wu J; Chen L; Wei J; Weiss H; Chauhan A
    Pharm Stat; 2020 May; 19(3):214-229. PubMed ID: 31749311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint.
    Mick R; Crowley JJ; Carroll RJ
    Control Clin Trials; 2000 Aug; 21(4):343-59. PubMed ID: 10913809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
    Sun X; Peng P; Tu D
    Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive seamless designs with interim treatment selection: a case study in oncology.
    Carreras M; Gutjahr G; Brannath W
    Stat Med; 2015 Apr; 34(8):1317-33. PubMed ID: 25640198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Curtailed two-stage designs with two dependent binary endpoints.
    Chen CM; Chi Y
    Pharm Stat; 2012; 11(1):57-62. PubMed ID: 22162348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An efficient algorithm to determine the optimal two-stage randomized multinomial designs in oncology clinical trials.
    Zhang Y; Mietlowski W; Chen B; Wang Y
    J Biopharm Stat; 2011 Jan; 21(1):56-65. PubMed ID: 21191854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated phase II/III clinical trials in oncology: a case study.
    Wang M; Dignam JJ; Zhang QE; DeGroot JF; Mehta MP; Hunsberger S
    Clin Trials; 2012 Dec; 9(6):741-7. PubMed ID: 23180870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.